Apoptosis and modulation of cell cycle control by synthetic derivatives of ursodeoxycholic acid and chenodeoxycholic acid in human prostate cancer cells

Cancer Letters

Volumn 199, Issue 2, 2003, Pages 157-167

  Choi, Yung Hyun ^a   Im, Eun Ok ^b   Suh, Hongsuk ^b   Jin, Youngeup ^b   Yoo, Young Hyun ^c   Kim, Nam Deuk ^b  

^a Dong Eui University   (South Korea)

^b Pusan National University   (South Korea)

^c Dong A University College of Medicine   (South Korea)

Author keywords

Apoptosis; Cell cycle arrest; p21 WAF1 CIP1; pRB; Synthetic bile acid derivatives

Indexed keywords

ANTINEOPLASTIC AGENT; BILE ACID; CHENODEOXYCHOLIC ACID DERIVATIVE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLINE; DNA FRAGMENT; HS 1183; HS 1199; HS 1200; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN; PROTEIN P21; PROTEIN PRB; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CHROMATIN CONDENSATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE CONSTRUCT; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REPORTER GENE;

EID: 0142156003     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00351-3     Document Type: Article

References (54)

1. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
2. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
3. Kato J.Y., Matsuoka M., Strom D.K., C D.K., Sherr J. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol. Cell. Biol. 14:1996;2713-2721.
4. Koff A., Giordano A., Desai D., Yamashita K., Harper J.W., Elledge S., Nishimoto T., Morgan D.O., Franza B.R., Roberts J.M. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science. 257:1992;1689-1694.
5. Dynlacht B.D., Flores O., Lees J.A., Harlow E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev. 8:1994;1772-1786.
6. DeGregori J., Leone G., Ohtani K., Miron A., Nevins J.R. E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev. 9:1995;2873-2887.
7. Guadagno T.M., Newport J.W. Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity. Cell. 84:1996;73-82.
8. Morgan D.O. Principles of CDK regulation. Nature. 374:1995;131-134.
9. Harper J.W., Elledge S.J. Cdk inhibitors in development and cancer. Curr. Opin. Genet. Dev. 6:1996;56-64.
10. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
11. Xiong Y., Hannon G., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
12. Waldman T., Kinzler K.W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:1995;5187-5190.
13. Datto M.B., Yu Y., Wang X.F. Functional analysis of the transforming growth factor (responsive elements in the WAF/Cip1/p21 promoter. J. Biol. Chem. 270:1995;28623-28628.
14. WAF1/CIP1 in human prostate carcinoma cells. J. Biol. Chem. 273:1997;10618-10623.
15. Choi Y.H., Lee W.H., Park K.Y., Zhang L. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn. J. Cancer Res. 91:2000;164-173.
16. Steinman R.A., Hoffman B., Iro A., Guillouf C., Liebermann D.A., El-Houseini M.E. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene. 9:1994;3389-3396.
17. Walsh K., Perlman H. Cell cycle exit upon myogenic differentiation. Curr. Opin. Genet. Dev. 7:1997;597-602.
18. Chen U., Chen S., Saha P., Dutta A. p21Cip1/Waf1 disrupts the recruitment of human Fen1 by proliferating-cell nuclear antigen into the DNA replication complex. Proc. Natl. Acad. Sci. USA. 93:1996;11597-11602.
19. Gartel A.L., Tyner A.L. The growth-regulatory role of p21 (WAF1/CIP1). Prog. Mol. Subcell. Biol. 20:1998;43-71.
20. Martinez J.D., Stratagoules E.D., LaRue J.M., Powell A.A., Gause P.R., Craven M.T., Payne C.M., Powell M.B., Gerner E.W., Earnest D.L. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr. Cancer. 31:1998;111-118.
21. Hofmann A.F. Chemistry and enterohepatic circulation of bile acids. Hepatology. 4:(suppl.):1984;4S-14S.
22. Martinez-Diez M.C., Serrano M.A., Monte M.J., Marin J.J. Comparison of the effects of bile acids on cell viability, and DNA synthesis by rat hepatocytes in primary culture. Biochim. Biophys. Acta. 1500:2000;153-160.
23. Rust C., Karnitz L.M., Paya C.V., Moscat J., Simari R.D., Gores G.J. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J. Biol. Chem. 275:2000;20210-20216.
24. Patel T., Bronk S.F., Gores G.J. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J. Clin. Invest. 94:1994;2183-2192.
25. Patel T., Roberts L.R., Jones B.A., Gores G.J. Dysregulation of apoptosis as a mechanism of liver disease: an overview. Semin. Liver Dis. 18:1998;105-114.
26. Powell A.A., LaRue J.M., Batta A.K., Martinez J.D. Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. Biochem. J. 356:2001;481-486.
27. Baek J.H., Kim J., Kang C., Lee Y.S., Kim K.W. Induction of apoptosis by bile acids in HepG2 human hepatocellular carcinoma cells. Korean J. Physiol. Pharmacol. 1:1997;107-115.
28. Park Y.H., Kim J., Baek J., Jung E., Kim T., Suh H., Park M.H., Kim K.W. Induction of apoptosis in HepG2 human hepatocellular carcinoma cells by a novel derivative of ursodeoxycholic acid (UDCA). Arch. Pharm. Res. 20:1997;29-33.
29. Im E.O., Lee S., Suh H., Kim K.W., Bae Y.T., Kim N.D. A novel ursodeoxycholic acid derivative induces apoptosis in human MCF-7 breast cancer cells. Pharm. Pharmacol. Commun. 5:1999;293-298.
30. Choi Y.H., Im E.O., Suh H., Jin Y., Lee W.H., Yoo Y.H., Kim K.W., Kim N.D. Apoptotic activity of novel bile acid derivatives in human leukemic T cells through the activation of caspases. Int. J. Oncol. 18:2001;979-984.
31. Im E.O., Choi Y.H., Paik K.J., Suh H., Jin Y., Kim K.W., Yoo Y.H., Kim N.D. Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells. Cancer Lett. 163:2001;83-93.
32. Suh H., Jung E.J., Kim T.H., Lee H.Y., Park Y.H., Kim K.W. Anti-angiogenic activity of ursodeoxycholic acid and its derivatives. Cancer Lett. 113:1997;117-122.
33. Kim D.K., Lee J.R., Kim A., Lee A., Yoo M.A., Kim K.W., Kim N.D., Suh H. Inhibition of initiation of simian virus 40 DNA replication in vitro by the ursodexocycholic acid and its derivatives. Cancer Lett. 146:1999;147-153.
34. Tada H., Shiho O., Kuroshima K., Koyama M., Tsukamoto K. An improved colorimetric assay for interleukin 2. J. Immunol. Methods. 93:1986;157-165.
35. Choi Y.H., Zhang L., Lee W.H., Park K.Y. Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int. J. Oncol. 13:1998;391-396.
36. Choi Y.H., Lee S.J., Nguyen P., Jang J.S., Lee J., Wu M.L., Takano E., Maki M., Henkart P.A., Trepel J.B. Regulation of cyclin D1 by calpain protease. J. Biol. Chem. 272:1997;28479-28484.
37. Rubin S.J., Hallahan D.E., Ashman C.R., Brachman D.G., Beckett M.A., Virudachalam S., Yandell D.W., Weichselbaum R.R. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J. Surg. Oncol. 46:1991;31-36.
38. Blake J., Roberts P.J., Faubion W.A., Kominami E., Gores G.J. Cystatin A expression reduces bile salt-induced apoptosis in a rat hepatoma cell line. Am. J. Physiol. 275:1998;G723-G730.
39. Qiao D., Stratagouleas E.D., Martinez J.D. Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. Carcinogenesis. 22:2001;35-41.
40. Faubion W.A., Guicciardi M.E., Miyoshi H., Bronk S.F., Roberts P.J., Svingen P.A., Kaufmann S.H., Gores G.J. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J. Clin. Invest. 103:1999;137-145.
41. Mahmoud N.N., Dannenberg A.J., Bilinski R.T., Mestre J.R., Chadburn A., Churchill M., Martucci C., Bertagnolli M.M. Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis. Carcinogenesis. 20:1999;299-303.
42. Sodeman T., Bronk S.F., Roberts P.J., Miyoshi H., Gores G.J. Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. Am. J. Physiol. Gastrointest. Liver Physiol. 278:2000;992-999.
43. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., Hull M.V., Lustig K.D., Mangelsdorf D.J., Shan B. Identification of a nuclear receptor for bile acids. Science. 284:1999;1362-1365.
44. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., Stimmel J.B., Willson T.M., Zavacki A.M., Moore D.D., Lehmann J.M. Bile acids: natural ligands for an orphan nuclear receptor. Science. 284:1999;1365-1368.
45. Wang H., Chen J., Hollister K., Sowers L.C., Forman B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell. 3:1999;543-553.
46. Rust C., Karnitz L.M., Paya C.V., Moscat J., Simari R.D., Gores G.J. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J. Biol. Chem. 275:2000;20210-20216.
47. Song C.S., Echchgadda I., Baek B.S., Ahn S.C., Oh T., Roy A.K., Chatterjee B. Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid x receptor. J. Biol. Chem. 276:2001;42549-42556.
48. Earnest D.L., Holubec H., Wali R.K., Jolley C.S., Bissonette M., Bhattacharyya A.K., Roy H., Khare S., Brasitus T.A. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res. 54:1994;5071-5074.
49. Heuman D.M., Mills A.S., McCall J., Hylemon P.B., Pandak W.M., Vlahcevic Z.R. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology. 100:1991;203-211.
50. Heuman D.M., Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology. 106:1994;1333-1341.
51. Rodrigues C.M.P., Fan G., Ma X., Kren B.T., Steer C.J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J. Clin. Invest. 101:1998;2790-2799.
52. Pines J. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem. J. 308:1995;697-711.
53. Fernandez P.L., Jares P., Rey M.J., Campo E., Cardesa A. Cell cycle regulators and their abnomalities in breast cancer. Mol. Pathol. 51:1998;305-309.
54. Li R., Waga S., Hannon G.J., Beach D., Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature. 371:1994;534-537.